ArticleReviews in cardiovascular medicine2026
Factors Associated With Hyperuricemia in Patients With Coronary Heart Disease.
Article in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate clinical factors associated with hyperuricemia (HUA) in patients with newly diagnosed coronary heart disease (CHD) and to evaluate the correlation of novel derived biomarkers with HUA, thereby providing a reference for clinical risk identification, prevention, and treatment. Methods: This retrospective study analyzed 2265 patients with newly diagnosed CHD (2019-2024) who were randomly assigned to a modeling group (n = 1812) and a validation group (n = 453); HUA was defined as serum uric acid (UA) ≥420 μmol/L. Least absolute shrinkage and selection operator (LASSO) regression and multivariate logistic regression were used to identify associated factors. A prediction model was constructed and evaluated using receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and calibration plots. Results: Independent factors associated with HUA included triglycerides (odds ratio (OR) = 1.097, 95% CI: 1.036-1.160), creatinine (OR = 1.030, 95% CI: 1.025-1.035), monocyte-to-high-density lipoprotein cholesterol ratio (MHR; OR = 1.447, 95% CI: 1.057-1.981), remnant cholesterol (RC; OR = 1.812, 95% CI: 1.406-2.337), and alcohol use (OR = 1.596, 95% CI: 1.202-2.119) (all Conclusion: MHR and RC are novel biomarkers associated with HUA risk in patients with new-onset CHD. When combined with traditional factors such as triglycerides and creatinine, these novel biomarkers support a multifactorial, integrated evaluation of HUA-related risk and serve as a reference for clinical risk stratification and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.